| Phase 13 trials |
|
Phase 1
|
NCT04040699 |
Sep 2019 → Sep 2022 |
HER2 positive breast carcinoma |
Peking University |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03847168 |
Jun 2019 → Dec 2022 |
breast cancer, gastroesophageal cancer |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT03619681 |
Sep 2018 → Jun 2022 |
breast cancer, gastric cancer |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
Completed
|
No outcome recorded
|
| Phase 27 trials |
|
Phase 2
|
NCT06998771 |
Jun 2025 → Jun 2028 expected |
carcinoma |
Shanghai JMT-Bio Inc. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06023758 |
Sep 2023 → Sep 2025 overdue |
carcinoma |
Peking University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05985707 |
Aug 2023 → Dec 2026 expected |
carcinoma |
Peking University Cancer Hospital & Institute |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04881929 |
Aug 2021 → Nov 2022 |
breast cancer |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT04521179 |
Dec 2020 → Jan 2022 |
— |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04165993 |
Dec 2019 → May 2021 |
breast cancer |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT03925974 |
Jun 2019 → May 2022 |
gastroesophageal cancer |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
Completed
|
No outcome recorded
|
| Phase 2/32 trials |
|
Phase 2/3
|
NCT07332533 |
Dec 2025 → Jun 2032 expected |
carcinoma |
Shanghai JMT-Bio Inc. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2/3
|
NCT05427383 |
Apr 2022 → Nov 2025 overdue |
gastric cancer |
Shanghai JMT-Bio Inc. |
Recruiting
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT07441460 |
Mar 2026 → Aug 2034 expected |
HER2 positive breast carcinoma |
Shanghai JMT-Bio Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06747338 |
Dec 2024 → Dec 2026 expected |
HER2 positive breast carcinoma |
Shanghai JMT-Bio Inc. |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05838066 |
Jul 2023 → Jul 2025 overdue |
breast carcinoma by gene expression profile |
Shanghai JMT-Bio Inc. |
Recruiting
|
No outcome recorded
|